Nanobiotix SA

Voting Rights and Shares Capital of the Company

13 Jan 2026 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

17 Dec 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

15 Dec 2025 02:30:00 By Nasdaq GlobeNewswire

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

24 Nov 2025 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 Nov 2025 02:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

13 Nov 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

11 Nov 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

03 Nov 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

31 Oct 2025 03:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

24 Oct 2025 02:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

15 Oct 2025 02:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

01 Oct 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

30 Sep 2025 16:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

29 Sep 2025 18:30:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

17 Sep 2025 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

12 Sep 2025 13:00:00 By Nasdaq GlobeNewswire

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

02 Sep 2025 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

27 Aug 2025 02:00:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

07 Jul 2025 16:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

10 Jun 2025 16:15:00 By Nasdaq GlobeNewswire